Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study
Abstract Background Peripheral nodal B‐cell lymphomas (PNBCL) represent the most common presentation of lymphomas in dogs. Multiagent CHOP (C = cyclophosphamide, H = hydroxydaunorubicin [Doxorubicin], O = Oncovin, P = prednisolone)‐based chemotherapy protocols have been widely accepted as gold stand...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Journal of Veterinary Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jvim.17222 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850268336007413760 |
|---|---|
| author | Charles Hawkes Joanna Morris Spela Bavcar Craig Wilkie Surajit Ray Charlotte Auquier Sarah Benjamin Juan Borrego Massó Sébastien Bottin Owen Davies Isabelle Desmas‐Bazelle Anat Einhorn Celia Figueroa‐Gonzalez Katerina Holenova Elisavet Kritsotalaki Kerry Peak Katherine Smallwood Elisabetta Treggiari Paola Valenti Miguel Garcia de laVirgen Quentin Fournier |
| author_facet | Charles Hawkes Joanna Morris Spela Bavcar Craig Wilkie Surajit Ray Charlotte Auquier Sarah Benjamin Juan Borrego Massó Sébastien Bottin Owen Davies Isabelle Desmas‐Bazelle Anat Einhorn Celia Figueroa‐Gonzalez Katerina Holenova Elisavet Kritsotalaki Kerry Peak Katherine Smallwood Elisabetta Treggiari Paola Valenti Miguel Garcia de laVirgen Quentin Fournier |
| author_sort | Charles Hawkes |
| collection | DOAJ |
| description | Abstract Background Peripheral nodal B‐cell lymphomas (PNBCL) represent the most common presentation of lymphomas in dogs. Multiagent CHOP (C = cyclophosphamide, H = hydroxydaunorubicin [Doxorubicin], O = Oncovin, P = prednisolone)‐based chemotherapy protocols have been widely accepted as gold standard 1st‐line treatment. CHOP‐25 and CHOP‐19 are most commonly prescribed but have never been directly compared. Objectives Our primary aim was to compare outcomes of dogs diagnosed with PNBCL, treated using a 1st‐line CHOP‐19 or CHOP‐25 protocol. A secondary objective was to determine the impact of protocol‐related variables on outcomes. Animals Five hundred two dogs from 16 European oncology referral centers. One hundred fifty‐five dogs were treated with CHOP‐19 and 347 dogs with CHOP‐25. Methods Retrospective, multicentric cohort study of dogs diagnosed with PNBCL between 2014 and 2021. Results The 6‐month, 1‐year, and median progression‐free survival (PFS) were 56.5% (95% confidence interval [CI], 49.2‐65.0), 14.1% (95% CI, 9.4‐21.0), and 196 days (95% CI, 176‐233) with CHOP‐19; and 56.4% (95% CI, 51.4‐61.9), 17% (95% CI, 13.4‐21.6), and 209 days (95% CI, 187‐224) with CHOP‐25. The 1‐year, 2‐year and median overall survival (OS) were 36.9% (95% CI, 29.7‐46.0), 13.5% (95% CI, 8.6‐21.1), and 302 days (95% CI, 249‐338) with CHOP‐19; and 42.8% (95% CI, 37.7‐48.7), 15.4% (95% CI, 11.7‐20.4), and 321 days (95% CI, 293‐357) with CHOP‐25. No significant difference in PFS and OS was found between the 2 protocols. Conclusions and Clinical Importance Our study confirmed similar outcomes for dogs with PNBCL treated with 1st‐line CHOP‐19 or CHOP‐25. Both protocols therefore could be used as a standard of care in future trials. |
| format | Article |
| id | doaj-art-a9de3b9e0b7d41e380f7bdfff453170a |
| institution | OA Journals |
| issn | 0891-6640 1939-1676 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Veterinary Internal Medicine |
| spelling | doaj-art-a9de3b9e0b7d41e380f7bdfff453170a2025-08-20T01:53:30ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762024-11-013863193320510.1111/jvim.17222Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort studyCharles Hawkes0Joanna Morris1Spela Bavcar2Craig Wilkie3Surajit Ray4Charlotte Auquier5Sarah Benjamin6Juan Borrego Massó7Sébastien Bottin8Owen Davies9Isabelle Desmas‐Bazelle10Anat Einhorn11Celia Figueroa‐Gonzalez12Katerina Holenova13Elisavet Kritsotalaki14Kerry Peak15Katherine Smallwood16Elisabetta Treggiari17Paola Valenti18Miguel Garcia de laVirgen19Quentin Fournier20The Royal (Dick) School of Veterinary Studies University of Edinburgh Roslin United KingdomUniversity of Glasgow Glasgow United KingdomThe Royal (Dick) School of Veterinary Studies University of Edinburgh Roslin United KingdomUniversity of Glasgow Glasgow United KingdomUniversity of Glasgow Glasgow United KingdomUniversity of Liege Liege BelgiumDavies Veterinary Specialists Hitchin United KingdomHospital Aúna Especialidades Veterinarias IVC‐Evidensia Valencia SpainAura Veterinary Guildford United KingdomBristol Vet Specialists Bristol United KingdomRoyal Veterinary College London United KingdomKoret School of Veterinary Medicine Rehovot IsraelRoyal Veterinary College London United KingdomWear Referrals Bradbury United KingdomSouthfields Veterinary Specialists Basildon United KingdomAnderson Moores Winchester United KingdomNorth Downs Specialists Referrals Bletchingley United KingdomOncopets Milan ItalyClinica Veterinaria Malpensa AniCura Milan ItalyHospital Aúna Especialidades Veterinarias IVC‐Evidensia Valencia SpainAura Veterinary Guildford United KingdomAbstract Background Peripheral nodal B‐cell lymphomas (PNBCL) represent the most common presentation of lymphomas in dogs. Multiagent CHOP (C = cyclophosphamide, H = hydroxydaunorubicin [Doxorubicin], O = Oncovin, P = prednisolone)‐based chemotherapy protocols have been widely accepted as gold standard 1st‐line treatment. CHOP‐25 and CHOP‐19 are most commonly prescribed but have never been directly compared. Objectives Our primary aim was to compare outcomes of dogs diagnosed with PNBCL, treated using a 1st‐line CHOP‐19 or CHOP‐25 protocol. A secondary objective was to determine the impact of protocol‐related variables on outcomes. Animals Five hundred two dogs from 16 European oncology referral centers. One hundred fifty‐five dogs were treated with CHOP‐19 and 347 dogs with CHOP‐25. Methods Retrospective, multicentric cohort study of dogs diagnosed with PNBCL between 2014 and 2021. Results The 6‐month, 1‐year, and median progression‐free survival (PFS) were 56.5% (95% confidence interval [CI], 49.2‐65.0), 14.1% (95% CI, 9.4‐21.0), and 196 days (95% CI, 176‐233) with CHOP‐19; and 56.4% (95% CI, 51.4‐61.9), 17% (95% CI, 13.4‐21.6), and 209 days (95% CI, 187‐224) with CHOP‐25. The 1‐year, 2‐year and median overall survival (OS) were 36.9% (95% CI, 29.7‐46.0), 13.5% (95% CI, 8.6‐21.1), and 302 days (95% CI, 249‐338) with CHOP‐19; and 42.8% (95% CI, 37.7‐48.7), 15.4% (95% CI, 11.7‐20.4), and 321 days (95% CI, 293‐357) with CHOP‐25. No significant difference in PFS and OS was found between the 2 protocols. Conclusions and Clinical Importance Our study confirmed similar outcomes for dogs with PNBCL treated with 1st‐line CHOP‐19 or CHOP‐25. Both protocols therefore could be used as a standard of care in future trials.https://doi.org/10.1111/jvim.17222canineCHOP‐19CHOP‐25lymphomaprogression‐free survival |
| spellingShingle | Charles Hawkes Joanna Morris Spela Bavcar Craig Wilkie Surajit Ray Charlotte Auquier Sarah Benjamin Juan Borrego Massó Sébastien Bottin Owen Davies Isabelle Desmas‐Bazelle Anat Einhorn Celia Figueroa‐Gonzalez Katerina Holenova Elisavet Kritsotalaki Kerry Peak Katherine Smallwood Elisabetta Treggiari Paola Valenti Miguel Garcia de laVirgen Quentin Fournier Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study Journal of Veterinary Internal Medicine canine CHOP‐19 CHOP‐25 lymphoma progression‐free survival |
| title | Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study |
| title_full | Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study |
| title_fullStr | Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study |
| title_full_unstemmed | Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study |
| title_short | Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study |
| title_sort | comparison of chop 19 and chop 25 for treatment of peripheral nodal b cell lymphoma in dogs a european multicenter retrospective cohort study |
| topic | canine CHOP‐19 CHOP‐25 lymphoma progression‐free survival |
| url | https://doi.org/10.1111/jvim.17222 |
| work_keys_str_mv | AT charleshawkes comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT joannamorris comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT spelabavcar comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT craigwilkie comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT surajitray comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT charlotteauquier comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT sarahbenjamin comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT juanborregomasso comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT sebastienbottin comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT owendavies comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT isabelledesmasbazelle comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT anateinhorn comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT celiafigueroagonzalez comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT katerinaholenova comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT elisavetkritsotalaki comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT kerrypeak comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT katherinesmallwood comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT elisabettatreggiari comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT paolavalenti comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT miguelgarciadelavirgen comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy AT quentinfournier comparisonofchop19andchop25fortreatmentofperipheralnodalbcelllymphomaindogsaeuropeanmulticenterretrospectivecohortstudy |